What factors influence the speed of results from peptide therapy: Top 3 Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database Scientific Reports Ipamorelin is a potent growth hormone releasing peptide that has some potential advantages over some of the others. , Although peptides seem to be doled out like aspirin, keep in mind that these are Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab